New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD ...Middle East

PR Newswire - News
STOCKHOLM, Oct. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, as well as new data...

Hence then, the article about new data from leqembi lecanemab irmb phase 3 clarity ad study and subcutaneous formulation to be presented at ctad was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD )

Apple Storegoogle play

Last updated :

Also on site :



Latest News